journal
https://read.qxmd.com/read/38484503/nationwide-survey-in-japan-of-the-causative-diseases-of-bloody-sputum-and-hemoptysis-in-departments-of-respiratory-medicine-at-university-hospitals-and-core-hospitals
#21
JOURNAL ARTICLE
Hiroaki Fujii, Yu Hara, Yasushi Obase, Shusaku Haranaga, Hidenori Takahashi, Masaharu Shinkai, Jiro Terada, Jun Ikari, Hideki Katsura, Kazuko Yamamoto, Takuji Suzuki, Etsuko Tagaya, Hiroshi Mukae, Takeshi Kaneko
BACKGROUND: The Guidelines for the Management of Cough and Sputum (2019) of the Japanese Respiratory Society (JRS) were the first internationally published guidelines for the management of sputum. However, the data used to determine the causative diseases of bloody sputum and hemoptysis in these guidelines were not obtained in Japan. METHODS: A retrospective analysis was performed using the clinical information of patients with bloody sputum or hemoptysis who visited the department of respiratory medicine at a university or core hospital in Japan...
March 13, 2024: Respiratory Investigation
https://read.qxmd.com/read/38460356/glasgow-prognostic-score-and-body-mass-index-predict-short-term-discontinuation-of-the-antifibrotic-agents-pirfenidone-and-nintedanib
#22
JOURNAL ARTICLE
Kazutaka Takehara, Yasuhiko Koga, Yoshimasa Hachisu, Mitsuyoshi Utsugi, Yuri Sawada, Yasuyuki Saito, Seishi Yoshimi, Masakiyo Yatomi, Hiroaki Tsurumaki, Yuki Shin, Ikuo Wakamatsu, Norimitsu Kasahara, Koichi Yamaguchi, Kazue Umetsu, Shunichi Kouno, Junichi Nakagawa, Noriaki Sunaga, Toshitaka Maeno, Takeshi Hisada
BACKGROUND: The antifibrotic agents pirfenidone and nintedanib have been shown to be effective in patients with idiopathic pulmonary fibrosis (IPF). However, discontinuation of antifibrotic drugs is a major clinical concern because of the lack of alternative treatment options. Therefore, we identified factors that may be useful for predicting the termination of antifibrotic agents. METHODS: We retrospectively recruited 280 IPF patients treated with antifibrotic drugs between 2009 and 2018 from seven regional core hospitals in Gunma prefecture, Japan...
March 8, 2024: Respiratory Investigation
https://read.qxmd.com/read/38452443/invalidity-of-jrs-atypical-pneumonia-prediction-score-in-omicron-variant-of-covid-19-pneumonia
#23
JOURNAL ARTICLE
Naoyuki Miyashita, Yasushi Nakamori, Makoto Ogata, Naoki Fukuda, Akihisa Yamura, Yoshihisa Ishiura, Tomoki Ito
BACKGROUND: We evaluated whether the Japanese Respiratory Society (JRS) atypical pneumonia prediction score can be adapted for the diagnosis of COVID-19 pneumonia due to Omicron BA.1, BA.2, and BA.5 subvariants. METHODS: We enrolled a total of 547 patients with community-acquired COVID-19 pneumonia. Of the COVID-19 pneumonia patients, 198 cases were the Omicron BA.1 subvariant, 127 cases were the Omicron BA.2 subvariant, and 222 cases were the Omicron BA.5 subvariant...
March 6, 2024: Respiratory Investigation
https://read.qxmd.com/read/38452442/comparison-of-the-outcomes-of-pneumocystis-jirovecii-pneumonia-in-rheumatoid-arthritis-patients-treated-with-and-without-biologics
#24
JOURNAL ARTICLE
Shin-Ichiro Ohmura, Hiroki Matsui, Toshiaki Miyamoto, Daisuke Shichi, Takayuki Masui, Katsutoshi Ichijo, Yuya Homma, Haruka Fujioka, Tatsuya Nagai, Kei Nakashima
BACKGROUND: To investigate the outcomes of Pneumocystis jirovecii pneumonia (PCP) between patients with rheumatoid arthritis (RA) treated with and without biologics before PCP onset. PATIENTS AND METHODS: We retrospectively included rheumatoid arthritis (RA) patients with PCP treated with and without biologics before PCP onset. The primary endpoints were 30-day and 180-day survival rates, and the secondary endpoint was severe PCP, including in-hospital death, intensive care unit admission, and requirement of respiratory support during hospitalization...
March 6, 2024: Respiratory Investigation
https://read.qxmd.com/read/38437758/advancements-in-pulmonary-alveolar-proteinosis-treatment-a-journey-from-discovery-to-gm-csf-inhalation-therapy
#25
EDITORIAL
Takuro Sakagami
No abstract text is available yet for this article.
March 3, 2024: Respiratory Investigation
https://read.qxmd.com/read/38428090/bacterial-profiles-detected-in-ventilator-associated-pneumonia-in-japan-a-systematic-review
#26
REVIEW
Hiroshi Moro, Nobumasa Aoki, Hiroyuki Matsumoto, Kazuya Tone, Hisayuki Shuto, Kosaku Komiya, Toshiaki Kikuchi, Nobuaki Shime
The primary objective of this study was to identify the predominant organisms associated with ventilator-associated pneumonia (VAP) in Japan. Studies on VAP conducted in Japan were systematically reviewed, and seven studies with a total of 374 cases were included. The detection rate of each bacterium and multidrug-resistant (MDR) pathogen was analyzed using the inverse variance method. Pseudomonas aeruginosa was identified as the predominant pathogen in 29.2 % of cases, followed by methicillin-resistant Staphylococcus aureus (MRSA) (12...
February 29, 2024: Respiratory Investigation
https://read.qxmd.com/read/38428089/favorable-treatment-response-of-bevacizumab-combined-chemotherapy-for-advanced-or-recurrent-invasive-mucinous-adenocarcinoma-of-the-lung-a-retrospective-observational-study
#27
JOURNAL ARTICLE
Kazushi Fujimoto, Akimasa Sekine, Eri Hagiwara, Masato Asaoka, Satoshi Ikeda, Tomohisa Baba, Shigeru Komatsu, Takashi Ogura
Invasive mucinous adenocarcinoma (IMA) of the lung is a rare variant of adenocarcinoma characterized by abundant intracytoplasmic mucin within the tumor. Although IMA has poor sensitivity to conventional chemotherapy regimens used for non-small cell lung cancer, we observed a better response to the bevacizumab (BEV) regimen. In this retrospective study, we aimed to investigate the response to BEV-combined regimens in patients with IMA. Among 16 consecutive patients diagnosed with IMA between January 2016 and December 2020 at our institution and treated with systemic chemotherapy, seven patients were treated with BEV-combined regimens...
February 28, 2024: Respiratory Investigation
https://read.qxmd.com/read/38422915/spontaneous-regression-of-acute-fibrinous-organizing-pneumonia-induced-by-covid-19-vaccination-a-case-report
#28
Sanshiro Haga, Ryota Otoshi, Akimasa Sekine, Taichi Kaneko, Chieri Yamada, Tomohisa Baba, Shigeru Komatsu, Tomoe Sawazumi, Tamiko Takemura, Takashi Ogura
A 42-year-old woman visited our hospital with complaints of fever, muscle pain, and dyspnea one week after receiving the coronavirus disease 2019 (COVID-19) vaccine. Chest high-resolution computed tomography showed a patchy consolidation and ground-glass attenuation in the both lungs, consistent with acute interstitial pneumonia. Transbronchial lung cryobiopsy revealed organizing pneumonia with marked intra-alveolar fibrin, and pathologically diagnosed as acute fibrinous organizing pneumonia (AFOP). Other causative diseases such as dermatomyositis was clinically ruled out, and COVID-19 vaccine-induced AFOP was diagnosed...
February 28, 2024: Respiratory Investigation
https://read.qxmd.com/read/38422914/first-ever-characterisation-of-the-effects-of-short-telomeres-in-a-singapore-interstitial-lung-disease-cohort
#29
JOURNAL ARTICLE
Michelle Li Wei Kam, Siao Ting Chong, Sock Hoai Chan, Jeffrey J Swigris, Ee Ling Chew, Yi Hern Tan, Joanne Yuen Yie Ngeow, Su Ying Low
BACKGROUND: Differences in disease behaviour and genotypes are described in Asian and Western interstitial lung disease (ILD) cohorts. Short leukocyte telomere length (LTL) correlates with poor outcomes in Western ILD cohorts but its significance in Asian populations is unknown. We aim to characterise the burden and clinical implications of short LTL in Singaporean ILD patients. METHODS: Patients diagnosed with ILD at Singapore General Hospital were prospectively recruited and compared against 36 healthy controls...
February 28, 2024: Respiratory Investigation
https://read.qxmd.com/read/38417355/cancer-immunotherapy-with-immune-checkpoint-inhibitors-and-infections-a-particular-focus-on-mycobacterial-infections
#30
REVIEW
Kohei Fujita, Paul T Elkington
Cancer treatment is undergoing a major transformation with the advent of immunotherapy with immune checkpoint inhibitors. These drugs, which have a different mechanism of action from conventional cytotoxic chemotherapy, are transforming treatment paradigms for many patients suffering from advanced cancer. On the other hand, they are often complicated by specific adverse events, known as immune-related adverse events (irAEs). Infections occurring during immunotherapy with immune checkpoint inhibitors have recently received increasing attention and sometimes are seen as part of irAEs...
February 27, 2024: Respiratory Investigation
https://read.qxmd.com/read/38412569/osimertinib-readministration-for-central-nervous-system-metastases-in-non-small-cell-lung-cancer-positive-for-egfr-activating-mutations
#31
JOURNAL ARTICLE
Yu Inutsuka, Eiji Iwama, Yoshimasa Shiraishi, Yasuto Yoneshima, Daisuke Shibahara, Kentaro Tanaka, Isamu Okamoto
BACKGROUND: Osimertinib shows pronounced efficacy for EGFR mutation-positive non-small cell lung cancer (NSCLC) including associated central nervous system (CNS) metastases. Tumors inevitably develop resistance to the drug, however. Osimertinib is sometimes readministered after completion of standard chemotherapy. To clarify which patients might receive benefit from osimertinib readministration, we have retrospectively assessed its efficacy with a focus on CNS metastases. METHODS: A retrospective analysis of medical records was performed for 21 patients who underwent osimertinib readministration at Kyushu University Hospital between March 2016 and April 2023...
February 26, 2024: Respiratory Investigation
https://read.qxmd.com/read/38401246/current-situation-of-management-of-spontaneous-pneumothorax-in-japan-a-cross-sectional-cohort-study
#32
JOURNAL ARTICLE
Hitoshi Igai, Noriyoshi Sawabata, Toshiro Obuchi, Noriyuki Matsutani, Kenji Tsuboshima, Shouichi Okamoto, Akihiro Hayashi
BACKGROUND: Limited epidemiological information is available on spontaneous pneumothorax. To address this gap, the Japan Society for Pneumothorax and Cystic Lung Disease (JSPCLD) conducted a nationwide retrospective survey to investigate the current epidemiology of spontaneous pneumothorax in Japan. METHODS: In this study, we conducted a retrospective cross-sectional cohort study to demonstrate the clinical features of spontaneous pneumothorax in one year from April 2019 to March 2020, compare patient characteristics and treatment outcomes between primary (PSP) and secondary spontaneous pneumothorax (SSP), and investigate the risk factors associated with in-hospital mortality among patients with SSP...
February 23, 2024: Respiratory Investigation
https://read.qxmd.com/read/38401245/risk-factor-of-non-tuberculous-mycobacterium-infection-in-patients-with-rheumatoid-arthritis-and-other-autoimmune-diseases-receiving-biologic-agents-a-multicenter-retrospective-study
#33
JOURNAL ARTICLE
Hiroki Ashizawa, Takahiro Takazono, Shin-Ya Kawashiri, Nana Nakada, Yuya Ito, Nobuyuki Ashizawa, Tatsuro Hirayama, Masataka Yoshida, Kazuaki Takeda, Naoki Iwanaga, Shinnosuke Takemoto, Shotaro Ide, Tomo Mihara, Shinya Tomari, Noriho Sakamoto, Yasushi Obase, Koichi Izumikawa, Katsunori Yanagihara, Atsushi Kawakami, Hiroshi Mukae
BACKGROUND: Evidence regarding the association of the usage of biologic agents (Etanercept, Tocilizumab, adalimumab and so on), such as anti-tumor necrosis factor α, with the incidence and risk factors of non-tuberculous Mycobacteria (NTM) infection is limited. Therefore, this study aimed to investigate the incidence and risk factors of NTM and their associations with biologic agents' usage, and also investigated the potential of Mycobacterium avium complex (MAC) antibodies as a predictor of NTM infection development...
February 23, 2024: Respiratory Investigation
https://read.qxmd.com/read/38395006/comparison-of-nintedanib-induced-gastrointestinal-adverse-events-between-patients-with-systemic-sclerosis-associated-interstitial-lung-disease-and-idiopathic-interstitial-pneumonias
#34
JOURNAL ARTICLE
Miyu Imai, Hiroko Okabayashi, Kimitaka Akaike, Shohei Hamada, Aiko Masunaga, Hidenori Ichiyasu, Takuro Sakagami
BACKGROUND: Gastrointestinal symptoms, such as diarrhea and nausea, are common adverse events associated with nintedanib. Systemic sclerosis is associated with a high prevalence of gastrointestinal symptoms that may increase with nintedanib administration. In clinical practice, we aimed to determine whether patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) experience more adverse gastrointestinal events associated with nintedanib than patients with idiopathic interstitial pneumonias (IIPs)...
February 22, 2024: Respiratory Investigation
https://read.qxmd.com/read/38316096/rapidly-progressive-interstitial-lung-disease-with-positive-anti-mda5-antibody-as-an-immune-related-complication-of-nivolumab-a-case-report
#35
Sayaka Kato, Koji Sakamoto, Tomonori Sato, Tomoko Kobayashi, Yuichiro Shindo, Masahiro Morise, Shintaro Iwama, Hiroshi Arima, Makoto Ishii
Clinically amyopathic dermatomyositis (CADM) with a positive anti-MDA5 antibody titer is often associated with lethal rapidly progressive interstitial lung disease (RP-ILD). Despite the widespread use of immune checkpoint inhibitors (ICIs) in practice, there is no report of CADM with positive anti-MDA5 antibodies as their immune-related complication. We present a case of malignant mesothelioma who developed RP-ILD accompanied by distinct skin manifestations following the administration of nivolumab. Postmortem assessment of stored samples revealed a pre-existing positive titer of anti-MDA5 antibody, further augmented following ICI use, suggesting the possible value of serum screening for better risk stratification of this lethal complication...
February 4, 2024: Respiratory Investigation
https://read.qxmd.com/read/38301531/legionella-prediction-score
#36
EDITORIAL
Naoyuki Miyashita
No abstract text is available yet for this article.
January 31, 2024: Respiratory Investigation
https://read.qxmd.com/read/38295613/the-occurrence-rate-of-haarlem-and-beijing-genotypes-among-middle-eastern-isolates-of-multi-drug-resistant-mycobacterium-tuberculosis-a-systematic-review-and-meta-analysis
#37
REVIEW
Kianoosh Ferdosnejad, Mohammad Sholeh, Rouhollah Abdolhamidi, Erfan Soroush, Seyed Davar Siadat, Samira Tarashi
Antibiotic resistance is a serious problem that poses a major challenge to tuberculosis control worldwide. Many developing countries still struggle with this infection in term of various aspects as it remains a major health concern. A number of developing countries are located in the Middle East, one of the world's most important regions. The control of this infection remains largely suboptimal despite intensive research in the field, and the mechanisms that lead to its progression have not yet been fully understood...
January 30, 2024: Respiratory Investigation
https://read.qxmd.com/read/38295612/corrigendum-to-transcutaneous-gas-monitoring-is-a-useful-tool-to-detect-respiratory-depression-during-bronchoscopy-performed-under-propofol-sedation-resp-invest-61-2023-793-799
#38
Nana Yazawa, Yusuke Nakamura, Akihiro Takemasa, Nobuhiko Uchida, Yoshitomo Kushima, Meitetsu Masawa, Hiroaki Okutomi, Sayo Soda, Naoya Ikeda, Ryo Arai, Kazuyuki Chibana, Seiji Niho, Yasuo Shimizu
No abstract text is available yet for this article.
January 30, 2024: Respiratory Investigation
https://read.qxmd.com/read/38281397/platypnoea-orthodeoxia-syndrome-in-covid-19-pneumonia-patients-an-observational-study
#39
JOURNAL ARTICLE
Masatoshi Hanada, Yuji Ishimatsu, Noriho Sakamoto, Nobuyuki Ashizawa, Hirotomo Yamanashi, Motohiro Sekino, Koichi Izumikawa, Hiroshi Mukae, Koya Ariyoshi, Takahiro Maeda, Tetsuya Hara, Shuntaro Sato, Ryo Kozu
This retrospective observational study aimed to assess the clinical characteristics of platypnea-orthodeoxia syndrome in patients with coronavirus disease 2019 (COVID-19) treated using mechanical ventilation or high-flow nasal canula. We analyzed 42 consecutive patients with COVID-19 from January 2020 to March 2022. The primary outcomes were the incidence of platypnea-orthodeoxia syndrome, the time with required long-term oxygen therapy, and short-term prognosis. Additionally, we examined the relationships between platypnea-orthodeoxia syndrome and COVID-19 severity, the time with long-term oxygen therapy, and short-term prognosis...
January 27, 2024: Respiratory Investigation
https://read.qxmd.com/read/38637059/krebs-von-den-lungen-6-levels-at-admission-predicts-exercise-induced-hypoxemia-before-and-after-discharge-in-patients-with-covid-19
#40
JOURNAL ARTICLE
Keisuke Morikawa, Kazuyuki Tabira, Hiroyuki Takemura, Shogo Inaba, Yuta Suzuki, Osamu Hataji
BACKGROUND: There are no reports of exercise-induced hypoxemia in patients with coronavirus disease 2019 (COVID-19). Additionally, the predictive factors and prevalence of exercise-induced hypoxemia are unknown. This study investigated the incidence and predictive factors of exercise-induced hypoxemia before and after discharge in patients with COVID-19. METHODS: We enrolled 77 patients diagnosed with COVID-19 who were hospitalized between November 2020 and October 2021 and who underwent a 6-min walk test before and after discharge...
May 2024: Respiratory Investigation
journal
journal
44017
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.